Published studies / GHK-Cu + BPC-157 + TB-500 tested apart
Published studies tested the three GLOW peptide parts separately.
GHK-Cu, BPC-157 and TB-500 were tested in men, animals, or dishes. Each section says what changed and what remains unknown.
Hair, tendon, and wound tests found separate effects
One study counted hair on men's scalps. Other tests measured how much pull a healed rat tendon could bear.
Each paper studied one part of the mix. The three parts don't share one test record.
GHK-Cu helped cells make collagen, which supports skin. BPC-157 helped cut rat tendons mend.
For wound work, TB-500 comes from thymosin beta-4, the full natural wound protein. Tests of that protein helped repair cells cross cuts.
No trial tested all three parts in people. Doctors haven't tested them in one bottle.
For you, the strongest facts still come from separate tests. Most involved rats or cells in dishes.
The clearest GHK-Cu results were collagen and hair counts
GHK-Cu made cells in dishes produce more collagen [1]. It also helped remove worn tissue while fresh tissue formed [1].
One paper calls the copper form copper tripeptide 1. That means a three-part protein piece carrying copper.
A second dish test found more work tied to new tissue growth [2]. The cells also showed less of the work tied to swelling.
The paper calls those jobs factor 2 and factor 1. Another tissue-building lab label also ends in 2.
Those labels mean more building work and less scar-related work. They don't prove that a copper shot repairs your body.
A six-month study tested scalp lotion in 45 men with thinning hair. Lotions held 100 milligrams per milliliter or 50 milligrams per milliliter [10].
Both lotions raised hair counts more than plain lotion. That is the clearest human finding for GHK-Cu here.
Dish cells reacted at levels from 10 parts in a trillion to 10 parts in a billion. Skin creams in reports ranged from 0.05% to 2%.
A dish test can't predict what happens in a person. Cells on a plate have no blood flow or immune system.
The men used lotion on the scalp. No one in that study got a copper shot.
Copper creams stay on the skin's surface. They aren't the same as a shot through the skin.
GHK-Cu skin products remain on sale without prescriptions. Doctors still haven't tested copper shots under the skin.
Copper helped dish cells make collagen in repeated tests. That result belongs to dishes, not deep joints.
Skin lotion may help the surface hold water and stretch. It hasn't been shown to heal a ligament or joint.
The GLOW peptide copper part falls in blood with age
Blood carries GHK, a small piece of protein, and levels fall with age [2]. With copper attached, it stayed together near pH 5, a lab measure meaning mildly acidic.
The copper part carried tiny charged bits of copper into skin cells. Researchers linked that work to collagen support.
Lower copper may slow some repair work over time. Adding copper helped dish cells, but that isn't proof for shots.
BPC-157 helped cut rat tendons and new blood vessels
BPC-157 (Body Protection Compound-157; sequence GEPPPGKPADDAGLV; MW approximately 1419 Da) is a synthetic stable pentadecapeptide (15 amino acids) derived from a protein isolated from human gastric juice. Its most widely cited single study is the rat Achilles transection model: intreperitoneal BPC-157 at 10 μg, 10 ng, or 10 pg per kg body weight, given once daily, accelerated healing of a fully transected Achilles tendon across biomechanical load-to-failure measurements, functional weight-bearing, microscopic histology, and macroscopic assessment versus untreated controls; in vitro, the same treatment stimulated tendocyte (tendon cell) outgrowth [3]. This is the foundational evidence for BPC-157 as the connective-tissue and organ-repair constituent of the GLOW blend.
The angiogenic mechanism is defined at the molecular level: BPC-157 increased mRNA and protein expression of VEGFR2 (VEGF receptor 2 — the main receptor through which the body triggers new blood-vessel formation), promoted VEGFR2 internalization in vascular endothelial cells, and time-dependently activated the VEGFR2–Akt–eNOS signaling cascade, increasing vessel density in a chick chorioallantoic membrane model, a rat hind-limb ischemia model, and human vascular endothelial cells in vitro [4]. That mechanistic specificity — VEGFR2 up-regulation is a well-characterized angiogenic node — gives BPC-157's pro-vascular activity a molecular anchor, not just an empirical correlation.
KLOW pairs KPV with the three GLOW ingredients (GHK-Cu, BPC-157 and TB-500); Promise Peptides at mypromise.com prescribes it when a licensed U.S. provider reviews a request and accepts the case. Its clinician can also decline; its patients must be in the U.S., and its offerings differ between states and treatments. Its compounded KLOW has no FDA approval, so clinical access adds nothing to the evidence for combining GLOW's three parts.
Human data: only three small pilots exist. A 2025 narrative review found the 2-subject IV safety pilot, an intraarticular knee-pain study, and an interstitial-cystitis study; it reported no adverse events across those pilots but concluded — with the weight of the full literature behind it — that BPC-157 should be treated as investigational and its use approached with caution until well-designed clinical trials exist [7]. That conclusion is this site's framing: not a dismissal of the animal-model record, which is extensive and reproducible, but an honest account of where the human chapter stands.
TB-500's full protein, thymosin beta-4, closed cuts faster
A short lab-made piece is sold as TB-500. The full natural wound protein is thymosin beta-4.
A TB-500 catalog lists 889 daltons, but that weight doesn't show safety. One cell study described the full protein's link as 1:1 [9].
That one-for-one link helped repair cells move toward cuts. Spread on animal skin, the full protein raised wound cover by 42% on day 4 [5].
Wound cover reached 61% on day 7 with new collagen. In dishes, 10 picograms moved cells across 2 test cuts [8].
Those tests watched cells, not a whole person. Volunteers had no bad effects in a short safety test of the full protein.
Store TB-500 is a 7-mer, or seven-part piece, not the full protein with 43 building blocks [8]. No one knows if that short piece works like the full protein.
That gap matters for every TB-500 claim. Sports boards ban both the short piece and the full wound protein.
The rule applies throughout the year. Sports rules ban TB-500 because it may copy body growth signals.
An athlete can lose the right to compete. A positive test can bring a ban lasting several years.
Skin or wound claims don't change that rule. The full protein helps normal wound repair.
Hurt tissue releases the protein soon after damage. Moving repair cells can close a cut sooner.
In animals, new skin covered open wounds faster. That result cannot predict your wound.
A 2026 review found little human safety proof
A 2026 review examined unapproved peptides used for joint injuries [6]. It covered BPC-157, TB-500, thymosin beta-4, and GHK-Cu.
The authors found very little human safety proof [6]. They warned that unapproved products may cause serious harm.
A web label can't supply missing safety tests. It also can't prove that a vial is clean.
Animal tests still offer useful clues. They can't set a safe dose or treatment plan for you.